logo-loader
viewSynnovia PLC

Synnovia playing catch-up

Synnovia playing catch-up
Trading update

Synnnovia PLC (LON:SYN) has released a trading update for the year to 31 March. The company continues to expect significant growth in revenue and profits, with progress remaining strong in the higher margin Industrial division.

However, profitability for the group as a whole will now be below previous expectations. Previously reported delays in new projects in the Films division were resolved as expected, but the catch-up during January-March has not been strong enough to offset the impacts on profits. Also within Films, there have been some cost escalations affecting profitability for the division.

The company has also announced that it will publish some revisions to previously reported revenues, with the adjustments being described as "non-material".

Changes to our forecasts

We are now forecasting revenue growth of 7% and earnings per share (EPS) growth of 2% for the full year (FY) to March 2019. Our new forecasts are below our previous forecasts by 2.4% at the revenue level and 7% at the EPS level.

For FY March 2020 we are lowering our EPS forecast by 12% but are still forecasting 18.6% EPS growth versus FY March 2019. Our new forecast assumes 1) delays in Films are resolved, 2) growth in both divisions, 3) growth will be partially offset by the cost escalations in Films.

Valuation

We are forecasting revenue growth of 9.7% and EPS growth of 18.6% for FY March 2020. This reflects the benefit of growth investments in recent years and improving underlying earnings (EBITDA) margins. We outline the drivers of EBITDA margins on p2 of this report.

The shares are now trading on a FY March 2020e price/earnings (P/E) multiple of 7.4x. We believe that this discount multiple reflects market concerns about the issues that have affected Films. We expect to see a material positive re-rating if the company can demonstrate steady progress towards market expectations during FY Mar 2020.

Year end Mar 31 2017 2018 Current 2020
         
Revenue £M 65.8 76.7 82.0 90.0
EBITDA (£M) 6.9 7.0 7.6 8.8
Underlying PBT 4.3 4.2 4.3 5.1
EPS (p) 11.5 9.5 9.7 11.5
         
 

We are forecasting revenue growth of 9.7% and EPS growth of 18.6% for FY March 2020

Margin drivers

Synnovia operates through two divisions:

Industrial designs and manufactures ball-bearing assemblies, and also plastic consumables used in the manufacture of boxes and packaging, as well as plastic consumables used in the manufacture of hydraulic and industrial hoses.

Films develops and manufactures high strength plastic films for industrial packaging applications, and also packaging for the food industry and other applications.

During FY March 2019, Synnovia has benefitted from strong growth in the Industrial division, which is fundamentally a higher margin business than Films; however, this beneficial mix effect has been offset by project delays that have occurred in Films as it has been adding new capacity. The net effect has been little change to EBITDA margins for FY March 2019 versus 2018.

In FY March 2020 we are forecasting growth from both divisions, together with non-recurrence of the delays in Films, leading to an improvement in group EBITDA margin.

Quick facts: Synnovia PLC

Price: - -

LSE:SYN
Market: LSE
Market Cap: -
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

19 hours, 46 minutes ago

4 min read